Subscribe
16 February 2015Americas

Canada slams Eli Lilly’s patent practices in lawsuit response

The Canadian government has given a scathing assessment of Eli Lilly’s patenting practices in its formal response to the pharmaceutical company’s CAD $500 million ($401 million) lawsuit against it.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Eli Lilly’s Dermira accuses Perrigo of infringing patents
22 October 2020   Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.


Editor's picks

Why AI is changing the patent rules faster than anyone can keep up
Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025

Editor's picks

Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025
Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025

More features

Delegates descend upon Washington, DC for AIPLA Annual Meeting
Novo Nordisk counters rival with $9bn bid for obesity drug developer
‘We're being attacked from all sides’: Thermo Fisher Scientific counsel
China trademarks rankings reveal new entries, hidden gems and big brands
Edwards defends key heart valve product from infringement threat
Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?
The hidden code in life sciences deals
Why AI is changing the patent rules faster than anyone can keep up